Peptide News Digest

#Duke-University

1 story

Clinical Trials · View digest

Duke's ETAPA Trial: Peptide Vaccine P30-EPS Met Its Safety Goals in 18 Adults With Hard-to-Treat Glioblastoma

In an abstract for the Society for Neuro-Oncology meeting, Duke researchers reported that 18 adults with newly diagnosed MGMT-unmethylated glioblastoma received up to seven doses of P30-EPS after radiation. The vaccine links cytomegalovirus pp65, survivin, and EphA2 peptides to a tetanus toxoid epitope, and was given with the immune stimulant Hiltonol. All treatment-related side effects were grade 2 or lower, 11 patients showed antigen-specific T-cell responses, and median progression-free and overall survival were 9.7 and 15.3 months in this single-arm study.